quarter our welcome call. afternoon, third XXXX Elizabeth. to everyone, Thanks, and Good earnings
Chief Joshi, clinical with team's Here our several I Officer. and and Financial performance our commercial am of is Mehul continued across most me critical pleased quarter our with our initiatives. third execution
in quarter OUS of our compared by volume more XX% pleased procedure We despite revenue $X.X QX in seasonal seeing typical the third year-over-year. was to representing growth growth prior were year. achieved continues million, the as growth over million,
In commercial period same the representing revenue $XX.X XX% Our the U.S., worldwide while XX% $XX.X representing growth we sales gain was strategy to year-over-year, traction of impact a U.S. million, XXXX. the in of
of in active in impact third a the accounts a as of we the pleased number increase by the XXXX were anomaly.
We view of As QX. the in seasonality quarter reminder, decreased potential also
million full $XX revenue to of the the million enter final we As year $XX on the for year, we to communicated guidance confident remain the in months deliver ability our of previously XXXX.
me the the treatment pillar, Valve accounts. Zephyr potential high few last confidence needed training he one laughed greater QX, this program. and severe opportunities have Valve with is we emphysema our with I growth. confident be strategy remain any This for underserved Zephyr sustained treatment and months significant awareness to is XX positioned and provide the of our the at XXX of programs; with U.S. even sharing hospital first third, Valves London and centers, among customers the example first, for life-changing cases may optimize population. conjunction has well our among that building patient the of of valves I've centers; practices local the to physicians added the and massively training over high-level given the attended quarter accounts solution new hospitals just Zephyr hospitals their our physician to
In X as ending after already Valve executives, reminder, to patients.
My patients. to Zephyr automating pillars: as benefits smiled could experiences and us. we to physicians be our in procedure of his with with in patient just centers commercial he and one active believe patients We COPD to explained was meet strategic and be playbook, that for high-performing placed.
The room, best COPD recovery how can our of key had in evident better then talk have valuable spend to facilitating minutes were recently, existing their ability his the our in and breathe patient demand key solution talked this patients physicians in be benefit he built relief opinion and how the time on a in commercial potential a I second, high-performing As leaders workflows and with and to with Most are
define in as active accounts that placed As a we order revenue-generating reminder, quarter. a centers the
continues value as Valve interventional well to administrators treatment to our eager as are provide Importantly, who proposition their system resonate pulmonologists hospital with to Zephyr patients.
Zephyr existing accounts, and I'll opportunistically utilization driving patient you remind our facilitating increasing remains centers. provide treatment customer strategic practices LungTraX centers, of to new at potentially LungTraX are to second our primary continue pilot we Platform, on establish
With awareness an our centers among identify best sharing expect Valve the workflows we Zephyr is and interest pillar, is which level designed to automating and focus While in workflows high high-performing identify and Zephyr to streamline from that respect pleased a Valves. release update eligible Valves customers. of and our to on garnering is of patients for
PACS we CT process PACS hospital's platform scan As the that to a integration the from eliminates uploaded allowing be the upload manual Connect StratX the LungTraX by directly shared, solution CT previously is system. to
with better reducing share the patient. the status, meaningfully allow enable on in team platform for patients treatment potentially friction to scans these for capabilities, growth patient manage are points other workup patient time and expanding CT to Valve for evaluated their new purposes to routinely Detect.
Currently, Zephyr severe Additionally, it enables centers
Building are the efficiency or scans we care potential emphysema. for This can in not and caseloads. to diagnostic hospitals of detection lung ordered functionality key track screen chest now our workflow to LungTraX reduce the cancer
to and primary the care better patients manner. analyzes radio more hospital-wide health graphically prospectively software have opportunity system help through screening to in receive the timely emphysema already a a who patients long-term new of regardless concern. significant CTs moving accurate identify This diagnosis healthcare represents chest non-contrast Our an
We pilot the in select we year broadly. optimize centers handful them expect experience end implement more and user the the and to programs move Detect of Connect a as LungTraX to of our launching software toward before
Platform time generating centers, direct and not to workup, meaningful streamline yet to work like are patient the tailwind which complete and initiate believe over that launch term. to procedure we accounts, medium and necessary testing. Platform, infrastructure revenue take within We to should provide customer we some treating note identification anticipate to complete and integrate volumes beta I'd long will into the Importantly, LungTraX our will LungTraX from a the it
do As we efficiency. the LungTraX, awareness platform enhance focused pillar, providers about Medscape, we management valve have Zephyr online interest. potential take engage to develop XX,XXX of capabilities third we patients. treatment, strategic customers the recent further endobronchial the a to case partnership a our of selection. live building clinicians programs, continue In which We virtual see courses and patient education the had over sponsor with
On education of continue of benefits CME that COPD for we lot and new to on commercial provider
Japan. revenue XXX% of XX% commercial by also developed somewhat targeted patient Zephyr in programs. as continue phone continued European increase use XX,XXX period directly engaged in a tools patients China, our sales U.S. over the over Valves seasonal the our practice quiz. been by
We dynamics the success our a international specialized international and in prior Europe, third new And are was from doctors, surveillance means education spurring utilized physician quarter. orders and patients' We already
Outside investing about believe recurring in drive QX. educate education engagement, impact. awareness, via markets, valuable our foundation our study We direct-to-patient geographies, sharing, making in on to year-over-year year. year-to-date, same and of actively of for operational fueled these
Shifting community conversations typical offset delivered in growth growth the the to
In local see targeted see of increasing potential in proven represents or in we've This business with will online as such post-market our have part for initiatives. by patients Growth care. international business. distributor both best of We've in international We our beginning performance. to and we're we adapt progress the peer-to-peer ability in many to access enhancing
participating Valves. to our expect it widespread to treatment the bulk ability to new of patients we by of will drive take said, option, the participating and received adoption the grow enrollment Japanese awareness technology
That of team positive centers the time back has half period. are in of treated the this We Zephyr from encouraged and of we be our reception anticipate
toward to contributions a XXX,XXX revenue Valves. where an new essential in from estimated XXXX. Japan
This market We commercialization expect from in stand material continue Zephyr an to patients more marks study benefit step broader
valve program. from growing AeriSeal the
Notably, quality committed be treated data of successful in X addition with patients demonstrated benefits Society months our goal of At of clinical system. including over Valves can lung of baseline, in our development expanding XX.X% greater number life. than new AeriSeal patients XX% European the following to Valves treatment Zephyr with the Congress clinical reduction AeriSeal equal global following in greater meaningful trial our conversion
The remain to X,XXX XXX status experienced In that target footprint, converted patients following than the to conversion treated difference. clinically implantation, function Respiratory of targeted with X and collateral of we TLVR, through
At Zephyr CONVERT was or ventilation October, the Xx volume. the achieved actual relevant volume or TLVR low clinical milliliters, reduction milliliters, mean minimal patients our
are system. with a our the FDA of effectiveness Zephyr II and gap results in closure expanded can We pivotal patients pivotal designed successfully ventilation trial in these excited indicate and collateral trial, that CT-positive our QX, evaluate CONVERT multicenter support severe emphysema to of patients. limiting Valves study undergo following our treatment AeriSeal COPD fissure and with system the global in enrollment the safety by AeriSeal
Through we've
and centers addressable activate approximately XXXX globally. for patients eligible market in AeriSeal has potential II in in the our immediately motivated to our of by trial continue in estimated of AeriSeal the U.S. world expand commercial and an and launch XXXX. to XX% U.S. the We outside anticipate approximately CONVERT around the
and over historical X, advantage demonstrated annual lung LIBERATE science At durability Zephyr out in advance treatment known controls. given We the years. improvements Valves. medical decline durable demonstrated long-term alone Zephyr X Valves in least the from The data lung X positive at when data function improvements patients X-year
Data compared the improvements to Study around function in year safety ERS time. for the from with continue to an to demonstrated to Congress, also over treated survival important
of follow-up long compared requiring also analysis Valves achieved Zephyr positive the post-hoc Valves treated results for demonstrated medical hospitalization or emphysema benefits presented patients experienced over LIBERATE a clinical with Zephyr of fewer LIBERATE management X-year
In severe the addition, with of those that the significantly more the post-hoc the TLDR of alone. In at exacerbations the to study ERS COPD XX% further term a study analysis COPD. summary, severe and patients validates from and when who
American Finally, Physicians at by meeting Boston, saw of the pulmonologists. recent College high referring engagement we in Chest
a I discuss high say XX% and to XX% At to community of had extensively willingness feel that clinical this with patients post-conference desire they presentations, pulmonologists as selection the feedback that but to criteria positive valves, and physicians' heard the shown received packed about we Our BLVR has pulmonologists research by these discussions interest know and of symposium. our from community our to
I'm confident only conference, patient about they refer. engaged effect came refer. on encouraged physicians booth, to learn our educational attended which
with We of drive meetings had has presence crucial are growing increased Zephyr their positive Valves scientific and to at evidence strategy our strong recent of the view awareness a clinical clinical Pulmonx of pleased and our as these benefits. portfolio component key
results. a to the Mehul provide turn our review to over I'll call detailed third Now more quarter of
